InChI key
DLTOEESOSYKJBK-UHFFFAOYSA-N
InChI
1S/C23H29N3O.2ClH/c27-19-18-25-16-14-24(15-17-25)12-5-13-26-22-8-3-1-6-20(22)10-11-21-7-2-4-9-23(21)26;;/h1-4,6-11,27H,5,12-19H2;2*1H
SMILES string
Cl[H].Cl[H].OCCN1CCN(CCCN2c3ccccc3C=Cc4ccccc24)CC1
assay
≥98% (HPLC)
form
solid
storage condition
desiccated
color
yellow
solubility
H2O: ~24 mg/mL
Quality Level
General description
Opipramol acts as an antidepressant and is chemically similar to tricyclic antidepressants. It is an atypical anxiolytic and antidepressant drug. Opipramol mainly acts on sigma receptors. It is usually found to be much effective in depressive disorder. It has the ability to prevent histamine, serotonin, dopamine and alpha-1 adrenergic receptors.
Biochem/physiol Actions
σ1/σ2 opioid receptor agonist; an antagonist at D2, 5HT2 and H1 receptors; atypical antidepressant, antipsychotic and anxiolytic
Atypical antidepressant, antipsychotic and anxiolytic
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
W E Müller et al.
Pharmacopsychiatry, 37 Suppl 3, S189-S197 (2004-11-18)
Although opipramol is structurally related to imipramine, it does not represent a tricyclic antidepressant drug as it does not inhibit the neuronal uptake of norepinephrine and/or serotonin. Unlike imipramine it is a rather potent sigma ligand with modest subclass selectivity
H-P Volz et al.
Pharmacopsychiatry, 37 Suppl 3, S214-S220 (2004-11-18)
So far, sigma-ligands have been investigated for several indications in human studies in functional diarrhea as a model of somatoform disorder (igmesine), depression (igmesine, opipramol), anxiety (opipramol and--in animal models--siramisine), schizophrenia (panamasine, SL 82.0715, rimcazole, DuP 734, BMY 14 802)
Opipramol as nighttime medication.
Ulrich Leutgeb
Deutsches Arzteblatt international, 106(18), 321-321 (2009-06-24)
[Pharmacokinetics and relative bioavailability of opipramol in the new INSIDON--sustained release preparation].
E B Nilsson et al.
Fortschritte der Neurologie-Psychiatrie, 66 Suppl 1, S13-S16 (1999-01-29)
[Opipramol (Insidon) in the treatment of somatoform disorders].
H J Freyberger et al.
Fortschritte der Neurologie-Psychiatrie, 66 Suppl 1, S25-S30 (1999-01-29)
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持
